Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EpiPen Medicaid Rebates Could Increase As Mylan, CMS Dispute Heats Up

Executive Summary

Mylan, agency take opposing views on whether the company has been overcharging Medicaid for EpiPen, which is currently classified as a generic for the purposes of program rebates.


Related Content

Medicaid Discount Classification: Will Trump And Grassley Tag Team Against Pharma?
Medicaid Rebates Will Get Broad OIG Review After EpiPen
Investors Relieved As Mylan Settlement Avoids Investigation
Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts